Solara Active Pharma Q2 FY26 Earnings Results

Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.

 

Q2 FY26 Earnings Results:

• Revenue from Operations: ₹314 crore, down 9.6% YoY and 1.9% QoQ from ₹320 crore in Q1 FY26.

• Net Loss: ₹10.1 crore, reversing from a profit of ₹7.9 crore in Q2 FY25 and ₹10.5 crore profit in Q1 FY26.

• EBITDA: ₹35.2 crore, down 42.8% YoY and 38.8% QoQ; EBITDA margin contracted to 11.3% from 17.7% in Q2 FY25.

• Gross Margin: 51.0%, modestly up 50 bps YoY but down 310 bps QoQ.

• Operating costs increased by 8% YoY and 10% QoQ due to one-time additional operating expenses and a temporary shutdown at Mangalore facility.

• Net debt reduced to ₹623 crore, down ₹153 crore from FY25 end.

• Focus areas on deleveraging, cost optimization, and maintaining product mix in regulated markets (~75% of revenue).

 

Management Commentary & Strategic Insights:

• MD & CEO Sandeep Rao stated that operational disruptions in Mangalore facility were temporary and expected to normalize soon.

• Strategic focus remains on profitable revenue growth driven by regulated markets and high-margin products.

• Emphasis on cost control and deleveraging for sustainable performance.

• The long-term outlook remains positive with ongoing investment in R&D and capacity expansion.

 

 

Q1 FY26 Earnings Results:

• Revenue: ₹320.13 crore, up 6.3% QoQ, down 12.1% YoY.

• PAT: ₹10.52 crore, recovered from loss the previous quarter.

• EBITDA: ₹57.5 crore, margin at 18%, up from 11.6% a year ago.

• Improved profitability attributed to gross margin expansion and better cost control.

 

To view the company’s previous earnings and latest concall transcripts, click here  to visit the Alphastreet India news channel.